Please ensure Javascript is enabled for purposes of website accessibility

Why 1 Analyst Predicts Moderna Stock Will Plunge Nearly 70%

By Keith Speights – Aug 18, 2021 at 5:55AM

Key Points

  • Bank of America analyst Geoff Meacham thinks that Moderna's share price could drop by around 70%.
  • His primary concern is that the vaccine maker's valuation is well beyond what its prospects warrant.
  • Assessing Moderna's valuation with a high level of confidence is difficult because of the uncertainties the company faces.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The vaccine stock could be priced for even more than perfection.

Some have taken to calling Moderna (MRNA -0.23%) the "Tesla of biotech." There are some distinct parallels between the two stocks. Both stocks have skyrocketed on the strength of impressive innovation. And both stocks have attained valuations that some find excessive.

Despite its detractors, Tesla has managed to hold onto most of the gains that it has generated over the last couple of years. Can Moderna do the same? Not everyone believes it can. Here's why one analyst predicts that Moderna stock will plunge nearly 70%.

A person looks through binoculars that show declining bar charts in both lenses.

Image source: Getty Images.

Ridiculous and impossible

Bank of America analyst Geoff Meacham wrote to investors earlier this month that Moderna's valuation has gone from "unreasonable to ridiculous." The day before Meacham's note, the vaccine stock hit a market cap of over $195 billion.

Meacham crunched some numbers about what it would take for Moderna to deserve that kind of valuation. Based on his analysis, the company would need to sell at least 1.5 billion doses of its COVID-19 vaccine every year for the next 17 years. Also, every candidate in Moderna's pipeline would need to be successful, and rack up combined peak sales of $30 billion.

The BofA analyst wryly commented, "These assumptions are, in our view, impossible to justify." However, Moderna's share price has fallen since then, with Meacham's note helping to knock the stock off its lofty perch.

Even after the decline over the last few days, though, Moderna's market cap is still hovering around $150 billion. Meacham thinks the stock could fall nearly 70%, to $115 per share, and a market cap in the ballpark of $46 billion.

What's Moderna really worth?

I don't believe that Moderna was really worth $195 billion earlier this month, and I don't think it's worth $150 billion now. So what is the company actually worth? It's a tough question to answer because there are so many uncertainties.

Moderna expects to rake in around $20 billion from its COVID-19 vaccine this year. If it could count on that level of revenue every year, the company's current valuation wouldn't be nearly as worrisome.

The problem is that it's not likely that Moderna will make that much recurring revenue after next year. Analysts project that sales in 2023 from the company's COVID-19 vaccine will probably be around $7.6 billion. While that estimate could prove to be too low, I suspect that in a scenario with annual booster doses, Moderna's sales wouldn't be significantly higher than the projection.

Moderna also could have another messenger RNA (mRNA) vaccine on the way in the not-too-distant future. The company plans to advance its experimental cytomegalovirus (CMV) vaccine mRNA-1647 into late-stage testing this year. If it's approved, Moderna thinks the vaccine could generate peak sales of between $2 billion and $5 billion.

My view is that a case could be made for Moderna's market cap to go higher than Meacham's target. Considering the potential of its other pipeline candidates and its growing cash stockpile, I wouldn't blink at a $70 billion valuation for the company. Again, though, there are way too many uncertainties to determine what Moderna is really worth with a high degree of confidence.

The big question

One of my biggest investing mistakes in the past has been to place too much emphasis on a fast-growing company's valuation. I opted not to buy stocks that I liked because I thought they were overpriced. And I kicked myself for it later.

Is Moderna a similar case? There are some common denominators. Like the stocks that I skipped over in the past, Moderna has a potentially game-changing technology. Moderna has also differentiated itself in the mRNA market, as pioneers in other new arenas have done.

On the other hand, Moderna has multiple competitors that could be equally successful in mRNA development. And Moderna has a long road to success with its pipeline candidates, because of the time required to conduct clinical studies and win regulatory approvals and authorizations.

Bank of America's Meacham thinks that Moderna is worth roughly $100 billion less than its current market cap. He could be right.

The big question for long-term investors, however, is whether if you hold this stock long enough you can still obtain a market-beating return. I think that's a possibility. But you might need to be willing to endure wrenching volatility along the way.

Bank of America is an advertising partner of The Ascent, a Motley Fool company. Keith Speights owns shares of Bank of America. The Motley Fool owns shares of and recommends Tesla. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.